What is Besunyen Holdings Co. Ltd. stock?

Besunyen Holdings Co. Ltd. Business Introduction

Business Summary

Besunyen Holdings Co. Ltd. (HKG: 0926) is a leading provider of functional tea products in China, specializing in therapeutic teas designed for weight management and digestive health. Founded in 2000, the company has evolved from a traditional herbal tea manufacturer into a comprehensive health and wellness group. Its products are widely recognized under the "Besunyen" brand, which has maintained a dominant market share in the Chinese functional tea segment for over two decades. The company integrates R&D, production, and omni-channel sales to provide consumers with natural, plant-based health solutions.

Detailed Business Modules

1. Core Functional Teas (The "Two Teas"):
The cornerstone of Besunyen’s revenue remains its two flagship products: Besunyen Detox Tea and Besunyen Slimming Tea (rebranded as Besunyen Fit Tea). These products are "Blue Cap" certified health foods by the State Administration for Market Regulation (SAMR), targeting consumers with constipation issues and those seeking body weight control.

2. Weight Management Medicines:
Expanding beyond herbal teas, Besunyen has ventured into the OTC medicine market through its Orlistat capsules. This product targets the clinical weight-loss market, providing a pharmaceutical alternative to its traditional herbal supplements.

3. Diversified Health & Beauty Products:
The company has diversified its portfolio to include nutritional supplements (e.g., probiotics, vitamins), meal replacements (shakes and bars), and functional skincare products. This module aims to capture the "Big Health" consumption trend among younger demographics.

4. E-commerce and New Retail:
Besunyen has transitioned from a pharmacy-heavy distribution model to a digital-first strategy. It operates flagship stores on Tmall, JD.com, and Pinduoduo, while aggressively utilizing Douyin (TikTok China) and Xiaohongshu for content marketing and live-streaming sales.

Summary of Business Model Characteristics

Branding + Distribution: Besunyen utilizes a "High-Frequency Marketing" model, investing heavily in brand awareness to drive pull-through sales across its massive network of over 400,000 retail pharmacies and supermarkets.
Asset-Light Operations: While maintaining its own production bases, the company focuses its core energy on brand management and supply chain coordination.
Regulatory Compliance: The company relies on its "Blue Cap" (Health Food) certifications, which act as a significant barrier to entry for new competitors in the regulated functional tea space.

Core Competitive Moat

· Brand Heritage: Besunyen is a household name in China for slimming tea, possessing high brand recall that reduces customer acquisition costs over the long term.
· Massive Distribution Network: A deeply entrenched offline sales network covering nearly all provinces in China, providing a physical moat that pure-play e-commerce brands lack.
· R&D and Intellectual Property: Holding numerous patents in herbal extraction and formulation, ensuring product efficacy and safety compared to uncertified "natural" teas.

Latest Strategic Layout

According to the 2023 Annual Report and 2024 Interim updates, Besunyen is pivoting toward "Digital Intelligence." This includes using Big Data to refine consumer profiles and developing "Short-Video + Live Streaming" as a primary sales engine. Additionally, the company is optimizing its product mix to reduce reliance on the "Two Teas" by scaling its Orlistat and probiotic lines to achieve a more balanced revenue structure.

Besunyen Holdings Co. Ltd. Development History

Development Characteristics

Besunyen’s history is characterized by rapid early growth driven by aggressive advertising, followed by a period of strategic restructuring and digital transformation to adapt to changing consumer habits and stricter regulatory environments.

Detailed Development Stages

Stage 1: Founding and Market Penetration (2000 - 2009)
Founded by Mr. Zhao Yihong in 2000, the company identified a gap in the market for convenient, effective herbal weight-loss solutions. Through massive television advertising campaigns, Besunyen became a national brand within five years. By 2009, it had established a dominant position in the detox and slimming tea categories.

Stage 2: IPO and Market Dominance (2010 - 2015)
In September 2010, Besunyen successfully listed on the Main Board of the Hong Kong Stock Exchange. During this period, the company expanded its production capacity and refined its "Blue Cap" product line. However, it also faced challenges from rising advertising costs and evolving food safety regulations.

Stage 3: Diversification and Crisis Management (2016 - 2020)
To counter the stagnation of the traditional tea market, Besunyen acquired various pharmaceutical and health assets. A significant milestone was the launch and rapid scaling of Besunyen Orlistat. The company navigated several regulatory shifts regarding health food labeling and claims during this time.

Stage 4: Digital Transformation and Multi-Brand Strategy (2021 - Present)
Besunyen has shifted its focus to "New Retail." It has successfully migrated a large portion of its sales to online platforms. The company is now positioning itself as a "comprehensive weight management and health solution provider," moving away from being seen only as a "tea company."

Analysis of Success and Challenges

Success Factors: Effective use of celebrity endorsements and "bombardment" marketing in the early 2000s; early acquisition of regulatory certifications; strong control over offline pharmacy channels.
Challenges: Heavy dependence on a single product category for many years made the company vulnerable to shifts in consumer taste; high selling and distribution expenses have historically pressured net profit margins.

Industry Introduction

Basic Situation of the Industry

Besunyen operates in the Chinese Functional Tea and Weight Management Market, a subset of the broader "Big Health" (Da Jian Kang) industry. This market includes health supplements, OTC weight-loss drugs, and functional beverages.

Key Market Data (2023-2024 Estimates):

Industry Trends and Catalysts

1. "Guochao" and Traditional Medicine: There is a resurgence in interest in Traditional Chinese Medicine (TCM) among Gen Z, which benefits companies like Besunyen that utilize herbal ingredients.
2. E-commerce Penetration: The shift from pharmacies to "Social Commerce" (Douyin, Xiaohongshu) is the primary catalyst for sales volume in the health sector.
3. Regulatory Tightening: The Chinese government continues to tighten "Blue Cap" regulations, which benefits established players with compliant manufacturing processes while weeding out smaller, non-compliant competitors.

Competitive Landscape

Besunyen faces competition from multiple fronts:
· Traditional Rivals: Brands like Yanree and Tong Ren Tang in the herbal space.
· Modern Startups: "Genki Forest" style functional beverage brands that offer low-calorie, trendy alternatives.
· Global Pharmaceutical Giants: Multinational firms providing advanced weight-loss medications (though often at a higher price point than Besunyen's Orlistat).

Industry Position of Besunyen

Besunyen remains the undisputed leader in the functional tea category in China. According to industry reports from Southern Medicine Economic Research Institute, Besunyen has consistently ranked No. 1 in market share for slimming and detox teas sold through retail pharmacies. While the company faces pressure in the "slimming" category from new drug formats, its transition into the Orlistat and probiotic markets has allowed it to maintain its status as a top-tier player in China’s weight management ecosystem.

Besunyen Holdings Co. Ltd. Financial Health Score

Based on the latest financial reports for 2024 and the interim results for the first half of 2025 (H1 2025), Besunyen Holdings Co. Ltd. (926.HK) is showing signs of a financial turnaround after a period of significant losses. The company's strategic shift toward pharmaceutical products and cost-cutting measures has stabilized its balance sheet.

Besunyen Holdings Co. Ltd. Development Potential

1. Strategic Pivot to "Dietary Drugs"

Besunyen is successfully reducing its decades-long reliance on its "Two Teas" (Detox and Slimming Tea). As of mid-2025, revenue from dietary drugs (including Orlistat) has risen to 38% of total sales. This pivot into the pharmaceutical OTC market provides a higher barrier to entry and stronger consumer trust compared to functional foods.

2. Business Partnership Reform Catalyst

The "Business Partnership System," fully implemented in 2024 across e-commerce and OTC segments, has transformed traditional departments into profit-oriented units. This has led to a significant reduction in employee benefit expenses (down RMB 68.6 million in 2024) and more agile responses to market trends on platforms like Douyin and Kuaishou.

3. "One Focus, Two Dimensions" Roadmap

The company’s latest roadmap focuses on Weight Management and Gastrointestinal Health. By expanding into probiotics, enzymes, and medical devices, Besunyen is positioning itself as a comprehensive health solutions provider rather than just a tea manufacturer.

4. Digital Retail and E-commerce Maturity

Besunyen has established 63 online shops across 18 platforms. Its ability to capitalize on major shopping festivals (like JD 618) and leverage O2O (Online-to-Offline) models suggests a strong grip on China's evolving digital consumption landscape.

Besunyen Holdings Co. Ltd. Pros and Risks

Company Upside (Pros)

Strong Brand Equity: With over 25 years in the market, Besunyen remains a household name in China for weight management, providing a low customer acquisition cost for new product launches.
Asset-Light & Efficient: The recent restructuring has streamlined operations, resulting in a positive total comprehensive income of RMB 16.8 million in 2024, reversing the massive loss of 2023.
Robust Distribution: Its offline network covers approximately 300,000 OTC pharmacies across 31 provinces, offering a massive physical footprint that many digital-only brands lack.

Company Risks

Fierce Market Competition: The weight loss market is saturated with global pharmaceutical giants and emerging wellness startups, putting constant pressure on Besunyen’s market share.
Vulnerability to Consumer Trends: The "functional tea" segment has faced declining interest as consumers shift toward science-backed clinical solutions, requiring constant R&D investment (which was actually reduced by 15.8% in 2024).
Regulatory Scrutiny: As the company shifts more toward OTC medicines, it faces stricter compliance requirements and quality control standards from health authorities.

How Do Analysts View Besunyen Holdings Co. Ltd. and the 926 Stock?

Heading into mid-2026, analyst sentiment regarding Besunyen Holdings Co. Ltd. (926.HK) reflects a "cautious wait-and-see" approach. As a veteran in China's therapeutic tea and weight-loss market, Besunyen is navigating a complex transition from traditional retail to a digital-first strategy. While its legacy brand remains strong, market observers are focused on whether its new product lines and e-commerce expansion can offset the headwinds in its core segments. Below is a detailed analysis from mainstream market viewpoints:

1. Core Institutional Views on the Company

Brand Resilience vs. Product Concentration: Most analysts acknowledge that Besunyen maintains a dominant position in the therapeutic tea category with its "Four Teas" (Detox, Slimming, Fit, and Relief teas). However, there is persistent concern regarding its reliance on a narrow product portfolio. The transition toward weight-loss medicines, specifically Besunyen Orlistat, is seen as a necessary but competitive pivot as the company seeks new growth engines beyond herbal teas.

Digital Transformation Progress: Analysts have noted the company’s aggressive push into "New Retail." By the end of 2024, Besunyen had established 63 online shops across 18 e-commerce platforms and actively utilized Douyin (TikTok China), Kuaishou, and Xiaohongshu for marketing. This shift is viewed as a critical step in reaching a younger, health-conscious demographic, though the high marketing costs associated with these platforms remain a drag on margins.

Operational Stabilization: Following the 2024 annual report, which showed a revenue of RMB 484.3 million (a decrease of 10.8% year-on-year), analysts are looking for signs of stabilization. The company’s ability to record a total comprehensive income of approximately RMB 16.8 million in 2024—reversing previous larger losses—suggests that cost-control measures and business optimizations are beginning to take effect.

2. Stock Ratings and Performance Outlook

As of early 2026, market consensus for 926.HK is largely categorized as "Neutral" or "Speculative Hold":

Rating Distribution: Due to its micro-cap status (Market Cap approx. HK$ 297 million), official coverage from major global investment banks is limited. Among boutique research firms and technical analysts, the stock is often classified as a "Contrarian" play—attractive to value investors looking for a turnaround but risky for those seeking short-term momentum.

Valuation and Price Targets:
Price-to-Book (P/B) Ratio: Currently trading at a low P/B of approximately 0.55x, indicating the stock may be undervalued relative to its assets.
Dividend Yield: The stock has historically offered a trailing dividend yield of over 6%, which attracts income-oriented investors, provided the company can maintain cash flow stability.
Price Forecasts: Short-term technical targets fluctuate around the HK$ 2.40 - HK$ 4.10 range, depending on the volatility of the Hong Kong small-cap market.

3. Risks and Challenges (The Bear Case)

Analysts highlight several key risks that could hinder the stock’s performance:
Intense Competition: The weight-loss and wellness market in China is increasingly crowded. New "internet-native" brands and international supplements are challenging Besunyen’s market share with aggressive pricing and hip branding.
Regulatory Oversight: As a provider of therapeutic teas and OTC medicines, Besunyen is highly sensitive to changes in health food and pharmaceutical regulations in China. Any tightening of advertising standards or ingredient approvals could impact sales.
Liquidity Risk: As a micro-cap stock, 926.HK suffers from relatively low trading volume, which can lead to high price volatility and difficulty for large institutional investors to enter or exit positions without significant slippage.

Summary

The consensus on Besunyen in 2026 is that the company is a legacy brand in a transformation phase. While the successful turnaround to profitability in 2024 provides a safety buffer, the stock is currently viewed as a value play rather than a high-growth AI or tech play. Investors are advised to monitor the company’s quarterly e-commerce sales growth and any potential breakthroughs in its "weight-loss medicine" segment as key indicators for a stock re-rating.

Besunyen Holdings Co. Ltd. (0926.HK) Frequently Asked Questions

What are the key investment highlights and main competitors of Besunyen Holdings Co. Ltd.?

Besunyen Holdings Co. Ltd. is a leading provider of therapeutic tea products in China, specifically dominating the weight-loss and laxative tea markets. The company’s core investment highlights include its strong brand recognition with flagship products like "Besunyen Detox Tea" and "Besunyen Slimming Tea," and its extensive nationwide distribution network covering over 400,000 retail outlets.
The company has recently pivoted towards an O2O (Online-to-Offline) strategy and expanded into the pharmaceutical and e-commerce sectors to diversify its revenue streams. Main competitors include traditional pharmaceutical companies like Tasly Pharmaceutical, health supplement brands such as By-Health, and various emerging "diet tea" brands sold primarily through social media platforms.

Is Besunyen's latest financial data healthy? What are the revenue, net profit, and debt conditions?

According to the 2023 Annual Results (the most recent full-year data), Besunyen reported a revenue of approximately RMB 543.4 million, representing a decrease compared to the previous year. The company recorded a net loss of approximately RMB 459.6 million for the year ended December 31, 2023, largely attributed to impairment losses on assets and increased marketing expenses in a competitive digital landscape.
Regarding its balance sheet, the company maintains a total debt-to-equity ratio that has been under pressure due to consecutive losses. Investors should note that while the company holds significant cash reserves, its operational cash flow has been impacted by the transition of its business model and market volatility.

Is the current valuation of Besunyen (0926.HK) high? How do the P/E and P/B ratios compare to the industry?

As of mid-2024, Besunyen’s valuation reflects its current turnaround phase. Because the company has reported net losses, the Price-to-Earnings (P/E) ratio is currently negative, which is common for companies in a deficit.
The Price-to-Book (P/B) ratio typically hovers at a low level (often below 0.5x), suggesting the stock is trading at a significant discount to its book value. Compared to the broader Personal Care and Health Products industry in Hong Kong, Besunyen is considered a "deep value" play or a speculative recovery stock, trading at much lower multiples than profitable peers like Vinda International or Hengan International.

How has Besunyen’s stock price performed over the past three months and year compared to its peers?

Besunyen’s stock price has faced downward pressure over the past year, significantly underperforming the Hang Seng Index and the healthcare sector. Over the last 12 months, the stock has seen a decline of over 40%, driven by disappointing earnings and thin trading liquidity.
In the short term (past three months), the stock has remained relatively stagnant or volatile at low price levels. Compared to peers in the health supplement space, Besunyen has lagged behind as investors favor companies with clearer growth trajectories in the post-pandemic health market.

Are there any recent positive or negative industry trends affecting Besunyen?

Positive Trends: There is an increasing consumer focus on "preventative health" and "natural weight management" among younger demographics in China. The growth of Douyin (TikTok China) and Xiaohongshu as sales channels provides Besunyen with opportunities to reach new customers directly.
Negative Trends: Regulatory scrutiny on "health food" (Blue Hat) claims remains very strict in China. Additionally, the rise of GLP-1 weight-loss medications (like Semaglutide) has shifted market attention away from traditional herbal slimming teas, posing a long-term structural challenge to the company's core product category.

Have any major institutions recently bought or sold Besunyen (0926.HK) shares?

Institutional interest in Besunyen has been relatively low in recent periods. The majority of shares are held by the founder, Mr. Zhao Yihong, through his holding companies. Recent filings indicate that institutional turnover is minimal, with some smaller specialized emerging market funds holding residual positions.
Investors should monitor HKEX Disclosure of Interests for any significant changes, as the low liquidity of the stock means that even small institutional sell-offs or buy-ins can cause significant price fluctuations.